Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
$RFTREES Refinitiv Eurozone ESG Select Index
NEMCF New Energy Metals Corp
SLCT Select Bancorp Inc
HPQ HP Inc
GOLD Barrick Gold Corp
DGNR Dragoneer Growth Opportunities Corp
EQMEF Equity Metals Corp
TS Tenaris SA
TRXC Transenterix Inc
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Price
Delayed
$539.44
Day's Change
5.55 (1.04%)
Bid
--
Ask
--
B/A Size
--
Day's High
543.99
Day's Low
529.31
Volume
(Light)

Today's volume of 268,543 shares is on pace to be much lighter than REGN's 10-day average volume of 1,073,315 shares.

268,543

REGN's position in the Biotechnology industry

Industry PeersREGNAMGNGILDINCYIONS

Summary

Company ProfileRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products...
Go to AMGN summary
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and...
Go to GILD summary
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from...
Go to INCY summary
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs...
Go to IONS summary
52-Week Change

VS. INDUSTRY
38.33%
2.81%
6.49%
16.72%
1.50%
Market Cap

VS. INDUSTRY
$57.0B
$144.5B
$84.1B
$20.5B
$8.5B
Beta

VS. INDUSTRY
0.2
0.7
0.4
0.8
1.2
Dividend Yield

VS. INDUSTRY
--
2.84%
4.06%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
19.51x
20.02x
69.69x
--
123.67x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$8.2B
$25.0B
$23.1B
$2.5B
$932.7M
Profit Margin

VS. INDUSTRY
38.28%
29.42%
5.33%
-13.62%
6.29%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
44.00%
13.96%
-10.51%
--
--
Revenue Growth (TTM)

VS. INDUSTRY
24.49%
6.80%
3.50%
16.55%
13.60%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.